UPDATE: Credit Suisse Reiterates Neutral Rating, Raises PT on Gilead Sciences

In a report published Wednesday, Credit Suisse reiterated its Neutral rating on Gilead Sciences GILD, and raised its price target from $54.00 to $65.00. Credit Suisse noted, “Slight Q3 beat driven primarily by higher product sales. GILD reported after the market close yesterday, posting an EPS of $1.00 (vs. $0.96/$0.93 for Credit Suisse/consensus). The beat was driven by higher product sales ($2.43B vs. $2.37B/$2.33B for Credit Suisse/consensus). Truvada delivered a strong Q3, posting sales of $800M (vs. $774M/$762M for Credit Suisse/consensus). GILD also raised guidance on 2012 net product sales from $8.8B-$9.0B to $9.1B-$9.2B. We made housekeeping changes to our model; there were no major changes. We are raising our 2012/2013/2014 EPS estimates to $.85/$4.64/$6.02 (from $3.83/$4.57/$5.94) respectively.” Gilead Sciences closed on Tuesday at $64.91.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsCredit Suisse
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!